Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab in SLE (EMBODY2)
NCT01261793Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2010
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of epratuzumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by UCB. Primary endpoint: Percent of Subjects Meeting Treatment Response Criteria According to a Combined Response Index at 48 weeks. Started Dec 2010; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01261793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261793.